Disability /Long-Term RA Reduced With Biologic | Arthritis Information

Share
 

New data demonstrating the safety and efficacy of EnbrelĀ® (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term wwas presented at the 2007 EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.

Biologics, such as etanercept, work by blocking the action of a naturally occurring protein in the body called 'tumor necrosis factor' that is involved in causing inflammation (2). When combined with methotrexate, etanercept, also known as an anti-TNF therapy, has been shown to halt radiographic damage in patients with moderate RA activity over multiple years - which means the disease is halted at that stage (3).

Professor Lars Klareskog of Karolinska Institute Karolinska University Sweden, said, "These strong data should give doctors the confidence to consider a biologic earlier in patients with aggressive and progressive rheumatoid arthritis, and patients should now have the prospect of less disability with a treatment which has also proven to have a good long-term safety".

The analysis includes over nine thousand patient years of data from a total of 2,054 patients who were monitored for serious adverse events (SAEs), serious and opportunistic infections, sepsis, malignancies and lymphomas. Overall rates of SAE's were similar to control groups (0.11 pt-yr and 0.17 pt/yr vs 0.11-0.20/pt yr), as were serious infections, and reports of opportunistic infection were rare (1).

Professor Emilio Martin Mola of the Rheumatology Unit at Hospital Universitario La Paz, Spain added: "With both earlier and continuous use of Enbrel we can prevent the debilitating affects of RA taking hold and maintain this response for many years. It's critical that appropriate funding for biologics is sourced to continue the fight against serious inflammatory diseases, such as RA."

http://www.medicalnewstoday.com/articles/74216.php
Copyright ArthritisInsight.com